The tweet was deleted by the author.
But we saved everything 🙂.
Summit Therapeutics announced a new clinical trial partnership with the ECOG-ACRIN Cancer Research Group to study ivonescimab in first-line biliary tract cancer. Shares are down 1.6% on the day at $15.83.
Summit Therapeutics and the ECOG-ACRIN Cancer Research Group have entered into a collaboration on a Phase II / III clinical trial to evaluate ivonescimab in first-line biliary tract cancer. Clinical trial site activations in the United States are expected to begin in the fourth quarter of 2026. Of the 68 analysts covering the company, 42 rate the stock a buy, while 2 suggest selling.
View post on X Loading...
Price is holding just above the MA-50 at $15.74, reflecting a split structure where shares remain below both the MA-20 and the MA-200. This positioning suggests that while sellers maintain near-term control, buyers have managed to defend key support so far. The recent advance unfolded within a broader bearish chart setup without a decisive breakout. The daily action fits within an ongoing negotiation between support and resistance levels, leaving direction unresolved.
To gauge whether the recent development is being absorbed into the price, traders should watch for a close above $16.15 to confirm sustained buying or a move below $15.74 to signal that gains are being reversed. The stock has maintained its recent chart structure, lacking a clear breakout or breakdown. From here, there is a 53% probability of upside and a 47% probability of downside over the next five trading days, with an expected range between $15.12 and $16.53. The longer-term weekly chart continues to show a mixed outlook.
Previously it was reported that Summit Therapeutics remained under technical pressure despite launching new clinical trials for ivonescimab in renal cell carcinoma. The latest partnership with ECOG-ACRIN expands the clinical agenda but leaves the longer-term technical outlook unresolved, making a sustained move above $16.15 the key level for any shift in momentum.